2Flo Ventures — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Vivacelle Bio develops phospholipid nanoparticle therapies (VBI-S and VBI-1) that restore intravascular volume and redirect excess nitric oxide to treat hypovolemia in patients with septic shock or severe blood loss.
BiotechHealthtechMedical DevicesChicago, US
Cuthbert Ormand Simpkins(Executive Officer, Director)Diane Simpkins(Co-Founder & Treasurer, Board of Directors)inConrad Epting(Founding Member / Scientific Consultant)inHarven DeShield(Executive Officer, Director)inPaul(CEO/CFO)Stephen N. Keith(Former CEO)in
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.